Cel Sci CorpCVM
What Cel Sci Corp does.
CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies with an emphasis on Multikine:
Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; and
L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$30.3M | -$36.4M | -$36.7M | -$32.4M | -$26.9M | -$25.4M |
| Free cash flow | -$17.9M | -$27.8M | -$18.9M | -$23.2M | -$18.9M | -$17.2M |
More on CVM.
- Cel Sci Corp summary
- Cel Sci Corp financial statements
- Cel Sci Corp key metrics
- Cel Sci Corp health scores and style box
- Cel Sci Corp earnings
- Cel Sci Corp dividends
- Cel Sci Corp valuation
- Cel Sci Corp ownership and insiders
- Cel Sci Corp peers
Figures from Cel Sci Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.